Summary

The global market for Stem Cells was estimated to be worth US$ 3381 million in 2024 and is forecast to a readjusted size of US$ 6906 million by 2031 with a CAGR of 10.9% during the forecast period 2025-2031.
Stem cells are a class of undifferentiated cells that are able to differentiate into specialized cell types. Commonly, stem cells come from two main sources: Embryos formed during the blastocyst phase of embryological development (embryonic stem cells) and Adult tissue (adult stem cells).
Market Driver:
The Stem Cells market is driven by increasing research and development in regenerative medicine and the growing demand for innovative treatments for chronic diseases. Stem cell therapy has shown promising results in treating conditions such as neurodegenerative disorders, cardiovascular diseases, and orthopedic injuries. Additionally, advancements in biotechnology, such as induced pluripotent stem cells (iPSCs) and CRISPR-based gene editing, are expanding the potential applications of stem cells in personalized medicine. Government and private sector investments in stem cell research, along with regulatory approvals for new therapies, are further propelling market growth.
Market Challenge:
Despite its potential, the Stem Cells market faces challenges related to ethical concerns, regulatory complexities, and high costs. The use of embryonic stem cells remains controversial, leading to restrictions in certain regions. Additionally, stem cell therapies require stringent regulatory approvals due to safety concerns, including tumor formation and immune rejection risks. The high cost of stem cell treatments and the complexity of large-scale manufacturing also pose barriers to widespread adoption. Overcoming these challenges requires continued research, improved standardization, and policy support to ensure the safe and ethical development of stem cell therapies.
Stem cell industry of the world's major players have Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, Medi - post, JCR Pharmaceutical, MolMed, Pharmicell, Anterogen, Takeda (TiGenix), CBR, ViaCord, Esperite, LifeCell, CCBC, VCANBIO, BOYA LIFE, Beike Biotechnology and International Medical, etc, It has a total market share of 45%.
This report aims to provide a comprehensive presentation of the global market for Stem Cells, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Stem Cells by region & country, by Type, and by Application.
The Stem Cells market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Stem Cells.
Market Segmentation
By Company
Osiris Therapeutics
NuVasive
Chiesi Pharmaceuticals
Medi-post
JCR Pharmaceutical
MolMed
Pharmicell
Anterogen
Takeda (TiGenix)
CBR
ViaCord
Esperite
LifeCell
CCBC
VCANBIO
BOYA LIFE
Beike Biotechnology
International Medical
Global Cord Blood Corporation
Beijing Health-Biotech Group
ABMD
Segment by Type
Stem Cell Storage
Stem Cell Pharmaceutical and Treatment
Segment by Application
Blood Disease
Cancer
Autoimmune Disease
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Stem Cells company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Stem Cells in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Stem Cells in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

ページTOPに戻る

Table of Contents

1 Market Overview
1.1 Stem Cells Product Introduction
1.2 Global Stem Cells Market Size Forecast (2020-2031)
1.3 Stem Cells Market Trends & Drivers
1.3.1 Stem Cells Industry Trends
1.3.2 Stem Cells Market Drivers & Opportunity
1.3.3 Stem Cells Market Challenges
1.3.4 Stem Cells Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Stem Cells Players Revenue Ranking (2024)
2.2 Global Stem Cells Revenue by Company (2020-2025)
2.3 Key Companies Stem Cells Manufacturing Base Distribution and Headquarters
2.4 Key Companies Stem Cells Product Offered
2.5 Key Companies Time to Begin Mass Production of Stem Cells
2.6 Stem Cells Market Competitive Analysis
2.6.1 Stem Cells Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by Stem Cells Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Stem Cells as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Stem Cell Storage
3.1.2 Stem Cell Pharmaceutical and Treatment
3.2 Global Stem Cells Sales Value by Type
3.2.1 Global Stem Cells Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Stem Cells Sales Value, by Type (2020-2031)
3.2.3 Global Stem Cells Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Blood Disease
4.1.2 Cancer
4.1.3 Autoimmune Disease
4.1.4 Others
4.2 Global Stem Cells Sales Value by Application
4.2.1 Global Stem Cells Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Stem Cells Sales Value, by Application (2020-2031)
4.2.3 Global Stem Cells Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
5.1 Global Stem Cells Sales Value by Region
5.1.1 Global Stem Cells Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Stem Cells Sales Value by Region (2020-2025)
5.1.3 Global Stem Cells Sales Value by Region (2026-2031)
5.1.4 Global Stem Cells Sales Value by Region (%), (2020-2031)
5.2 North America
5.2.1 North America Stem Cells Sales Value, 2020-2031
5.2.2 North America Stem Cells Sales Value by Country (%), 2024 VS 2031
5.3 Europe
5.3.1 Europe Stem Cells Sales Value, 2020-2031
5.3.2 Europe Stem Cells Sales Value by Country (%), 2024 VS 2031
5.4 Asia Pacific
5.4.1 Asia Pacific Stem Cells Sales Value, 2020-2031
5.4.2 Asia Pacific Stem Cells Sales Value by Region (%), 2024 VS 2031
5.5 South America
5.5.1 South America Stem Cells Sales Value, 2020-2031
5.5.2 South America Stem Cells Sales Value by Country (%), 2024 VS 2031
5.6 Middle East & Africa
5.6.1 Middle East & Africa Stem Cells Sales Value, 2020-2031
5.6.2 Middle East & Africa Stem Cells Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Stem Cells Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Stem Cells Sales Value, 2020-2031
6.3 United States
6.3.1 United States Stem Cells Sales Value, 2020-2031
6.3.2 United States Stem Cells Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Stem Cells Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Stem Cells Sales Value, 2020-2031
6.4.2 Europe Stem Cells Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Stem Cells Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Stem Cells Sales Value, 2020-2031
6.5.2 China Stem Cells Sales Value by Type (%), 2024 VS 2031
6.5.3 China Stem Cells Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Stem Cells Sales Value, 2020-2031
6.6.2 Japan Stem Cells Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Stem Cells Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Stem Cells Sales Value, 2020-2031
6.7.2 South Korea Stem Cells Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Stem Cells Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Stem Cells Sales Value, 2020-2031
6.8.2 Southeast Asia Stem Cells Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Stem Cells Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Stem Cells Sales Value, 2020-2031
6.9.2 India Stem Cells Sales Value by Type (%), 2024 VS 2031
6.9.3 India Stem Cells Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Osiris Therapeutics
7.1.1 Osiris Therapeutics Profile
7.1.2 Osiris Therapeutics Main Business
7.1.3 Osiris Therapeutics Stem Cells Products, Services and Solutions
7.1.4 Osiris Therapeutics Stem Cells Revenue (US$ Million) & (2020-2025)
7.1.5 Osiris Therapeutics Recent Developments
7.2 NuVasive
7.2.1 NuVasive Profile
7.2.2 NuVasive Main Business
7.2.3 NuVasive Stem Cells Products, Services and Solutions
7.2.4 NuVasive Stem Cells Revenue (US$ Million) & (2020-2025)
7.2.5 NuVasive Recent Developments
7.3 Chiesi Pharmaceuticals
7.3.1 Chiesi Pharmaceuticals Profile
7.3.2 Chiesi Pharmaceuticals Main Business
7.3.3 Chiesi Pharmaceuticals Stem Cells Products, Services and Solutions
7.3.4 Chiesi Pharmaceuticals Stem Cells Revenue (US$ Million) & (2020-2025)
7.3.5 Chiesi Pharmaceuticals Recent Developments
7.4 Medi-post
7.4.1 Medi-post Profile
7.4.2 Medi-post Main Business
7.4.3 Medi-post Stem Cells Products, Services and Solutions
7.4.4 Medi-post Stem Cells Revenue (US$ Million) & (2020-2025)
7.4.5 Medi-post Recent Developments
7.5 JCR Pharmaceutical
7.5.1 JCR Pharmaceutical Profile
7.5.2 JCR Pharmaceutical Main Business
7.5.3 JCR Pharmaceutical Stem Cells Products, Services and Solutions
7.5.4 JCR Pharmaceutical Stem Cells Revenue (US$ Million) & (2020-2025)
7.5.5 JCR Pharmaceutical Recent Developments
7.6 MolMed
7.6.1 MolMed Profile
7.6.2 MolMed Main Business
7.6.3 MolMed Stem Cells Products, Services and Solutions
7.6.4 MolMed Stem Cells Revenue (US$ Million) & (2020-2025)
7.6.5 MolMed Recent Developments
7.7 Pharmicell
7.7.1 Pharmicell Profile
7.7.2 Pharmicell Main Business
7.7.3 Pharmicell Stem Cells Products, Services and Solutions
7.7.4 Pharmicell Stem Cells Revenue (US$ Million) & (2020-2025)
7.7.5 Pharmicell Recent Developments
7.8 Anterogen
7.8.1 Anterogen Profile
7.8.2 Anterogen Main Business
7.8.3 Anterogen Stem Cells Products, Services and Solutions
7.8.4 Anterogen Stem Cells Revenue (US$ Million) & (2020-2025)
7.8.5 Anterogen Recent Developments
7.9 Takeda (TiGenix)
7.9.1 Takeda (TiGenix) Profile
7.9.2 Takeda (TiGenix) Main Business
7.9.3 Takeda (TiGenix) Stem Cells Products, Services and Solutions
7.9.4 Takeda (TiGenix) Stem Cells Revenue (US$ Million) & (2020-2025)
7.9.5 Takeda (TiGenix) Recent Developments
7.10 CBR
7.10.1 CBR Profile
7.10.2 CBR Main Business
7.10.3 CBR Stem Cells Products, Services and Solutions
7.10.4 CBR Stem Cells Revenue (US$ Million) & (2020-2025)
7.10.5 CBR Recent Developments
7.11 ViaCord
7.11.1 ViaCord Profile
7.11.2 ViaCord Main Business
7.11.3 ViaCord Stem Cells Products, Services and Solutions
7.11.4 ViaCord Stem Cells Revenue (US$ Million) & (2020-2025)
7.11.5 ViaCord Recent Developments
7.12 Esperite
7.12.1 Esperite Profile
7.12.2 Esperite Main Business
7.12.3 Esperite Stem Cells Products, Services and Solutions
7.12.4 Esperite Stem Cells Revenue (US$ Million) & (2020-2025)
7.12.5 Esperite Recent Developments
7.13 LifeCell
7.13.1 LifeCell Profile
7.13.2 LifeCell Main Business
7.13.3 LifeCell Stem Cells Products, Services and Solutions
7.13.4 LifeCell Stem Cells Revenue (US$ Million) & (2020-2025)
7.13.5 LifeCell Recent Developments
7.14 CCBC
7.14.1 CCBC Profile
7.14.2 CCBC Main Business
7.14.3 CCBC Stem Cells Products, Services and Solutions
7.14.4 CCBC Stem Cells Revenue (US$ Million) & (2020-2025)
7.14.5 CCBC Recent Developments
7.15 VCANBIO
7.15.1 VCANBIO Profile
7.15.2 VCANBIO Main Business
7.15.3 VCANBIO Stem Cells Products, Services and Solutions
7.15.4 VCANBIO Stem Cells Revenue (US$ Million) & (2020-2025)
7.15.5 VCANBIO Recent Developments
7.16 BOYA LIFE
7.16.1 BOYA LIFE Profile
7.16.2 BOYA LIFE Main Business
7.16.3 BOYA LIFE Stem Cells Products, Services and Solutions
7.16.4 BOYA LIFE Stem Cells Revenue (US$ Million) & (2020-2025)
7.16.5 BOYA LIFE Recent Developments
7.17 Beike Biotechnology
7.17.1 Beike Biotechnology Profile
7.17.2 Beike Biotechnology Main Business
7.17.3 Beike Biotechnology Stem Cells Products, Services and Solutions
7.17.4 Beike Biotechnology Stem Cells Revenue (US$ Million) & (2020-2025)
7.17.5 Beike Biotechnology Recent Developments
7.18 International Medical
7.18.1 International Medical Profile
7.18.2 International Medical Main Business
7.18.3 International Medical Stem Cells Products, Services and Solutions
7.18.4 International Medical Stem Cells Revenue (US$ Million) & (2020-2025)
7.18.5 International Medical Recent Developments
7.19 Global Cord Blood Corporation
7.19.1 Global Cord Blood Corporation Profile
7.19.2 Global Cord Blood Corporation Main Business
7.19.3 Global Cord Blood Corporation Stem Cells Products, Services and Solutions
7.19.4 Global Cord Blood Corporation Stem Cells Revenue (US$ Million) & (2020-2025)
7.19.5 Global Cord Blood Corporation Recent Developments
7.20 Beijing Health-Biotech Group
7.20.1 Beijing Health-Biotech Group Profile
7.20.2 Beijing Health-Biotech Group Main Business
7.20.3 Beijing Health-Biotech Group Stem Cells Products, Services and Solutions
7.20.4 Beijing Health-Biotech Group Stem Cells Revenue (US$ Million) & (2020-2025)
7.20.5 Beijing Health-Biotech Group Recent Developments
7.21 ABMD
7.21.1 ABMD Profile
7.21.2 ABMD Main Business
7.21.3 ABMD Stem Cells Products, Services and Solutions
7.21.4 ABMD Stem Cells Revenue (US$ Million) & (2020-2025)
7.21.5 ABMD Recent Developments
8 Industry Chain Analysis
8.1 Stem Cells Industrial Chain
8.2 Stem Cells Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Stem Cells Sales Model
8.5.2 Sales Channel
8.5.3 Stem Cells Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer